Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types

Fig. 2

Analysis of EBF3 and TBC1D16 methylation in endometrial, prostate and breast cancers. Differentially methylated EBF3 and TBC1D16 CpG sites were analysed in Illumina 450k array DNA methylation data of a Teschendorff et al. dataset (accession number GSE67116 [14]) for endometrial hyperplasia (H, n = 8, in blue), primary endometrial tumours (P, n = 33, in red), lymph node metastases (LN, n = 11, in green), cervical/vaginal metastases (n = 26, magenta), ovarian metastases (n = 5, orange) and abdominal metastases (n = 8, black). b Aryee et al. dataset (accession number GSE38240[15]) for normal prostate (n = 4, blue) and prostate cancer metastases (n = 8, red). c Mathe et al. dataset (accession number GSE78758 [16]) for normal breast (N, n = 4, in blue), primary triple-negative breast cancer tumours (P, n = 23, in red) and lymph node metastases (n = 12, green); *P < 0.05, **P < 0.01

Back to article page